Search research articles
Contact Us
Filters
Showing results (11-20 of 372) with videos related to
Page
of 38
Sort By:
La Revue Du Praticien
|
November 10, 2009
[Multiple bone myelomas]
Murielle Roussel, Thomas Gastinne, Xavier Leleu
La Revue Du Praticien
|
March 22, 2006
[Prognostic factors and new treatments of multiple myeloma]
Xavier Leleu, Valérie Coiteux, Thierry Facon
Medecine Sciences : M/S
|
December 5, 2017
[Circulating exosomal microRNA as biomarkers in mutiple myeloma]
Salomon Manier, Xavier Leleu, Hervé Avet-Loiseau
Clinicoeconomics and Outcomes Research : CEOR
|
February 25, 2025
Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective
Christian Siegfried, Miyuru Amarapala, Xavier Leleu, et al.
Hematology/Oncology Clinics of North America
|
September 8, 2018
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond
Marion Magierowicz, Cécile Tomowiak, Xavier Leleu, et al.
Drugs of the Future
|
August 27, 2011
New Therapeutic Approaches for Waldenstrom Macroglobulinemia
Jennifer Stedman, Aldo Roccaro, Xavier Leleu, et al.
Bulletin Du Cancer
|
August 11, 2011
[IMiDs in hematology]
Mathieu Wémeau, Jordan Gauthier, Xavier Leleu, et al.
Hematological Oncology
|
April 22, 2017
Age-related health care disparities in multiple myeloma
Mathieu Puyade, Gautier Defossez, François Guilhot, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 23, 2012
Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia
Viviane Gnemmi, Xavier Leleu, François Provot, et al.
Annals of Hematology
|
December 29, 2017
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Xavier Leleu, Francesca Gay, Anne Flament, et al.
Page
of 38
Search research articles
Search
Showing results (11-20 of 372) with videos related to
Sort By:
Page
of 38
La Revue Du Praticien
|
November 10, 2009
[Multiple bone myelomas]
Murielle Roussel, Thomas Gastinne, Xavier Leleu
La Revue Du Praticien
|
March 22, 2006
[Prognostic factors and new treatments of multiple myeloma]
Xavier Leleu, Valérie Coiteux, Thierry Facon
Medecine Sciences : M/S
|
December 5, 2017
[Circulating exosomal microRNA as biomarkers in mutiple myeloma]
Salomon Manier, Xavier Leleu, Hervé Avet-Loiseau
Clinicoeconomics and Outcomes Research : CEOR
|
February 25, 2025
Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective
Christian Siegfried, Miyuru Amarapala, Xavier Leleu, et al.
Hematology/Oncology Clinics of North America
|
September 8, 2018
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond
Marion Magierowicz, Cécile Tomowiak, Xavier Leleu, et al.
Drugs of the Future
|
August 27, 2011
New Therapeutic Approaches for Waldenstrom Macroglobulinemia
Jennifer Stedman, Aldo Roccaro, Xavier Leleu, et al.
Bulletin Du Cancer
|
August 11, 2011
[IMiDs in hematology]
Mathieu Wémeau, Jordan Gauthier, Xavier Leleu, et al.
Hematological Oncology
|
April 22, 2017
Age-related health care disparities in multiple myeloma
Mathieu Puyade, Gautier Defossez, François Guilhot, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 23, 2012
Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia
Viviane Gnemmi, Xavier Leleu, François Provot, et al.
Annals of Hematology
|
December 29, 2017
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Xavier Leleu, Francesca Gay, Anne Flament, et al.
Page
of 38